With the Furman Inquiry Panel expected to report imminently and the UK CMA’s digital post-merger review ongoing, our TMT experts look forward to unpicking these developments and a topical discussion with Philip Marsden, Kirsten Edwards-Warren and David Parker.
For more information on this event, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...